article thumbnail

Amgen Completes Onyx Pharmaceuticals Tender Offer

socalTECH

Thousand Oaks-based Amgen reported this morning that it has completed its tender offer for Onyx Pharmaceuticals , and now expects its acquisition to complete today. billion net of estimated cash at Onyx. Amgen said the deal is worth $9.7

article thumbnail

Nexsan Updates S-1

socalTECH

In a sign that Thousand Oaks-based Nexsan might be ramping up its IPO efforts again, after a delay last year, the firm filed an updated S-1 this week. The provider of data storage equipment reported that it had net income of $0.5M in net income of $19.28M in revenues for the three months ended September 30, 2010.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Will Facebook's IPO Unbottle Southern California's Pipeline?

socalTECH

The firm reported net income of $1 billion on revenues of $3.7 Will the filing of an IPO by Menlo Park-based Facebook unclock the pipeline of would-be Southern Calfornia IPOs? Facebook filed for its IPO Wednesday afternoon, saying that it is looking to raise up to $5 billion, in what is expected to be the biggest IPO since Google.

article thumbnail

Bio Roundup: Mylan’s Shock, Hillary’s 3%, Duchenne Lessons & More

Xconomy

—Amgen (NASDAQ: AMGN ) of Thousand Oaks, CA, said that the FDA rejected its drug etelcalcetide (Parasbiv) , a treatment for patients with an excess of damaging hormone release because of chronic kidney disease. . Alex Lash contributed to this report. Reprints | Share: UNDERWRITERS AND PARTNERS.

Pricing 40